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The human SAMHD1 protein is a novel retroviral restriction factor expressed in myeloid cells. Previous
work has correlated the deoxynucleotide triphosphohydrolase activity of SAMHD1 with its ability to
block HIV-1 and SIVmac infection. SAMHD1 is comprised of the sterile alpha motif (SAM) and histidine–
aspartic (HD) domains; however the contribution of these domains to retroviral restriction is not
understood. Mutagenesis and deletion studies revealed that expression of the sole HD domain of
SAMHD1 is sufﬁcient to achieve potent restriction of HIV-1 and SIVmac. We demonstrated that the HD
domain of SAMHD1 is essential for the ability of SAMHD1 to oligomerize by using a biochemical assay.
In agreement with previous observations, we mapped the RNA-binding ability of SAMHD1 to the HD
domain. We also demonstrated a direct interaction of SAMHD1 with RNA by using enzymatically-active
puriﬁed SAMHD1 protein from insect cells. Interestingly, we showed that double-stranded RNA inhibits
the enzymatic activity of SAMHD1 in vitro suggesting the possibility that RNA from a pathogen might
modulate the enzymatic activity of SAMHD1 in cells. By contrast, we found that the SAM domain is
dispensable for retroviral restriction, oligomerization and RNA binding. Finally we tested the ability of
SAMHD1 to block the infection of retroviruses other than HIV-1 and SIVmac. These results showed that
SAMHD1 blocks infection of HIV-2, feline immunodeﬁciency virus (FIV), bovine immunodeﬁciency
virus (BIV), Equine infectious anemia virus (EIAV), N-tropic murine leukemia virus (N-MLV), and
B-tropic murine leukemia virus (B-MLV).
& 2012 Elsevier Ltd. All rights reserved.Introduction
Infection of primary macrophages and dendritic cells by
Simian Immunodeﬁciency virus (SIVmac) requires the accessory
protein Vpx, which is encoded in the SIV genome (Ayinde et al.,
2010). SIVmac particles without Vpx (SIVDVpx) are unable to infect
primary macrophages. Vpx is essential for both SIV infection of
primary macrophages and viral pathogenesis in vivo (Belshan
et al., 2006; Fletcher et al., 1996; Gibbs et al., 1995; Hirsch et al.,
1998). Vpx is incorporated into viral particles suggesting that it
might be acting immediately after viral fusion in the target cells
(Jin et al., 2001; Kappes et al., 1993; Park and Sodroski, 1995;
Selig et al., 1999). Viral reverse transcription is prevented in
primary macrophages when cells are infected with either Vpx-
deﬁcient SIVmac or HIV-2 (Bergamaschi et al., 2009; Fujita et al.,
2008; Goujon et al., 2007; Kaushik et al., 2009; Srivastava et al.,ll rights reserved.
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du (F. Diaz-Griffero).2008). These experiments suggest that when Vpx is incorporated
into viral particles, the virus overcomes a pre-reverse transcrip-
tion block in macrophages and dendritic cells. Remarkably, Vpx
also increases the ability of HIV-1 to infect macrophages and
dendritic cells when Vpx is incorporated into HIV-1 particles or
supplied in trans (Goujon et al., 2008; Sunseri et al., 2011). This
suggests that the block imposed by macrophages to SIVDVpx is
similar to the one imposed by macrophages to HIV-1.
Recent work identiﬁed SAMHD1 as the protein that blocks
infection of SIVDVpx, HIV-2DVpx and HIV-1 before reverse tran-
scription in macrophages and dendritic cells (Hrecka et al., 2011;
Laguette et al., 2011). However, SIV, HIV-2 and HIV-1 expressing
Vpx overcome the SAMHD1-dependent restriction (Hrecka et al.,
2011; Laguette et al., 2011). Mechanistic studies have suggested that
Vpx induces the proteasomal degradation of SAMHD1 (Berger et al.,
2011; Hrecka et al., 2011; Laguette et al., 2011). Interestingly, the C-
terminal region of SAMHD1 contains a Vpx binding motif, which is
important for the ability of Vpx to degrade SAMHD1 (Laguette et al.,
2012; Lim et al., 2012; Zhang et al., 2012). In addition, ﬁndings by
Lim et al. (2012) have suggested that the SAM domain of SAMHD1 is
important for the ability of Vpx to induce SAMHD1 degradation.
Fig. 1. Contribution of the different domains of SAMHD1 to restriction of HIV-1. Wild type human SAMHD1 protein is depicted in the top ﬁgure. The numbers of the amino acid
residues at the boundaries of the SAMHD1 domains are indicated. The HD domain boundaries used for these studies are based on the published structure (Goldstone et al., 2011).
SAMHD1 variants are shown, with the broken lines indicating deleted sequences (A). Human monocytic U937 cells stably expressing the indicated mutant and wild type
SAMHD1 proteins (B) were challenged with increasing amounts of HIV-1-GFP (C). As control, U937 cells stably transduced with the empty vector LPCX were challenged with
HIV-1-GFP. (D) Quantiﬁcation of dATP levels on PMA-treated U937 cells expressing the indicated SAMHD1 variant was performed as described in Materials and methods. SAM,
sterile alpha motif; HD, histidine–aspartic.
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aspartic (HD) domain. SAM domains are protein interaction modules
that mediate interaction with other SAM domains or non-SAM
domain-containing proteins (Rice et al., 2009). Moreover, SAM
domains in other proteins bind a speciﬁc sequence of DNA acting
as either transcription activators or repressors (Qiao and Bowie,
2005). The HD domain is found in a super family of enzymes with a
predicted phosphohydrolase activity (Zimmerman et al., 2008). In
agreement, recent work has demonstrated that SAMHD1 is a dGTP-
regulated deoxynucleotide triphosphohydrolase that might be
involved in decreasing the overall cellular levels of triphosphodeox-
ynucleotides (Goldstone et al., 2011; Kim et al., 2012; Lahouassa
et al., 2012b; Powell et al., 2011). This evidence agrees with the
hypothesis that an overall decrease in the level of dNTPs is
responsible for the block imposed to lentiviral infection.
The SAM and HD domains have been extensively studied on
other proteins; however, the contribution of the different
domains of SAMHD1 to HIV-1 restriction has not been investi-
gated. This work explores the contribution of the different
domains of SAMHD1 to HIV-1 restriction. By performing a series
of deletion constructs, we found that the expression of the sole
HD domain of SAMHD1 in U937 cells is sufﬁcient to potently
block HIV-1 infection. By contrast we showed that the SAM
domain seems to be dispensable for restriction. Using biochemical
assays, we demonstrated that the HD domain of SAMHD1 is the
basic requirement for the ability of SAMHD1 to oligomerize and
bind RNA. Furthermore, we explored the ability of SAMHD1 and
the HD domain to block infection by different retroviruses.Results
Contribution of the different domains of SAMHD1 to retroviral
restriction
The recently discovered restriction factor SAMHD1 comprises
of a SAM and HD domain. Although the enzymatic activity of the
HD domain is required for the ability of SAMHD1 to block HIV-1
and SIVmac infection (Goldstone et al., 2011; Lahouassa et al.,
2012b; Powell et al., 2011), the contribution of the different
regions of the SAMHD1 protein to restriction is not understood.
To understand the contribution of the SAM and HD domain to
lentiviral restriction, we generated a series of deletion constructs
to ﬁnd the minimal requirements for potent restriction (Fig. 1A).
The different SAMHD1 variants were stably expressed in the
human monocytic cell line U937 by using the LPCX vector system
(Fig. 1B), as previously described (Brandariz-Nunez et al., 2012).
U937 cells stably expressing SAMHD1 variants were induced to
differentiation by PMA treatment (Schwende et al., 1996). Differ-
entiated U937 cells were challenged with increasing amounts of
HIV-1 containing the green ﬂuorescent protein as a reporter (HIV-
1-GFP) (Fig. 1C and Table 1). Overall these studies showed that
expression of the SAMHD1 variant 112–582, which contains only
the HD domain, is sufﬁcient to block HIV-1 infection. In agreement,
SAMHD1 variants D164–319, 1–328 and HD206AA that have either
a defective or deleted HD domain completely lost their ability to
block HIV-1 infection (Fig. 1C and Table 1). Because deletion of
the SAM domain in the variant 112–626 did not affect HIV-1
Table 1
Phenotypes of SAMHD1 variants.
SAMHD1 variant HIV-1 restrictiona Oligomerizationb RNA bindingc Localizationd Cellular dATP levele
WT þ þþþ þþþ N Low
1–150 ND   ND ND
151–328 ND   NþC ND
15–626 þ þþþ þþ C Low
D45–110  þþþ þþþ N High
D164–319   þþþ N High
112–626 þ þþþ þþþ C Low
1–328   þþ N High
112–582 þ þþþ þþþ C Low
329–626 ND  þ NþC ND
HD206AA  þ þþ N High
WT, wild type; ND, not determined.
a Restriction was measured by infecting PMA-treated U937 cells stably expressing the indicated SAMHD1 variants with HIV-1-GFP. After 48 h, the percentage of GFP-
positive cells (infected cells) was determined by ﬂow cytometry. ‘‘þ ’’ indicates restriction; ‘‘ ’’ indicates absence of restriction.
b SAMHD1-FLAG variants were assayed for their ability to oligomerize with SAMHD1-HA, as described in Materials and methods. ‘‘þþþ ’’ indicates 100%
oligomerization, which corresponds to the amount of SAMHD1-HA that oligomerizes with wild type SAMHD1-FLAG; ‘‘þ ’’ indicates 30% oligomerization; ‘‘ ’’ indicates
that oligomerization was not detected. Similar results were obtained in three independent experiments.
c SAMHD1-FLAG variants were assayed for their ability to interact with RNA as described in Materials and methods. ‘‘þþþ ’’ is the binding to RNA achieved by wild type
SAMHD1; ‘‘þþ’’ indicates 60% of binding; ‘‘þ ’’ indicates 30% of binding; ‘‘ ’’ indicates that binding was not detected. Similar results were obtained in three
independent experiments.
d Subcellular localization of SAMHD1 variants was determined as described in Materials and methods. For each experiment, 200 cells were counted (Table S1). ‘‘N’’
indicates nuclear localization; ‘‘C’’ indicates cytoplasmic localization; ‘‘NþC’’ indicates localization throughout the cell.
e The cellular dATP levels were determined as described in Materials and methods and are shown in Fig. 1D. ‘‘High’’ indicates similar dATP levels to the one observed in
PMA-treated control U937 cells stably transduced with the empty vector LPCX. ‘‘Low’’ indicates similar dATP levels observed in PMA-treated U937 cells expressing wild
type SAMHD1, ND: Not Determined.
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pensable for restriction. In agreement with our previous ﬁndings
that SAMHD1 nuclear localization is not necessary for restric-
tion, the SAMHD1 variant 15–626, which is missing the nuclear
localization signal (NLS), potently restricts HIV-1. Because
SAMHD1 decreases the cellular levels of dNTPs in PMA-
differentiated U937 cells, we next measured dNTP levels in
differentiated U937 cells expressing the different SAMHD1
variants (Fig. 1D and Table 1). In agreement with the notion
that the HD domain is required for enzymatic activity, we found
that constructs with an intact HD domain decreased the cellular
levels of dNTPs (Fig. 1D and Table 1).
Overall these mapping studies suggested that the HD domain
of SAMHD1 is sufﬁcient to achieve potent restriction of HIV-1.
Moreover, these studies suggested that the SAM domain is
dispensable for restriction.
Oligomerization of SAMHD1
Structural studies revealed that the recombinant HD domain
protein of SAMHD1 produced in bacteria is dimeric (Goldstone
et al., 2011). We wanted to know whether SAMHD1 is oligomer-
ized in mammalian cells. Next we evaluated the biochemical
ability of SAMHD1 containing a FLAG tag (SAMHD1-FLAG) to
interact with SAMHD1 containing an HA tag (SAMHD1-HA). For
this purpose, we cotransfected similar amounts of both SAMHD1-
HA and SAMHD1-FLAG. Cells were lysed, and SAMHD1-FLAG was
immunoprecipitated by using anti-FLAG beads. Proteins eluted by
the FLAG peptide were separated by SDS-PAGE gels and analyzed
by Western blotting using anti-HA and anti-FLAG antibodies
(Fig. 2). In agreement with the notion that SAMHD1 forms
oligomers, SAMHD1-FLAG interacts with SAMHD1-HA (Fig. 2).
These results suggested that SAMHD1 forms oligomers when
expressed in mammalian cells.
Hetero-oligomerization of mutant and wild type SAMHD1 proteins
We next wanted to analyze the contribution of oligomeriza-
tion to HIV-1 restriction by SAMHD1. Moreover, the ability ofSAMHD1 to form oligomers is used as a surrogate assay to
evaluate proper folding of the protein. For this purpose, we
studied the ability of the different SAMHD1-FLAG variants to
interact with a wild type SAMHD1-HA (Fig. 3 and Table 1).
Interestingly, we observed that only SAMHD1-FLAG variants that
contain an intact HD domain such as 15–626, D45–110, 112–626
and 112–582 showed the ability to interact with SAMHD1-HA
(Fig. 3 and Table 1). By contrast, deletion constructs where the HD
domain was affected were deﬁcient for oligomerization (Fig. 3
and Table 1). These results suggested that the HD domain is the
main determinant for the oligomerization ability of SAMHD1.
Surprisingly, the SAMHD1 variant HD206AA, which is the muta-
tion on the active site of SAMHD1, showed a reproducible
decrease on oligomerization (Fig. 3 and Table 1). These results
suggested that the HD domain of SAMHD1 is the main oligomer-
ization determinant of the protein and is required for restriction.SAMHD1 variants binding to RNA
Recent experiments demonstrated the ability of SAMHD1 to
interact with nucleic acids (Goncalves et al., 2012). This work
showed that SAMHD1 preferentially binds RNA by testing the
ability of SAMHD1 from total mammalian or bacterial extracts to
bind the interferon-stimulatory DNA sequence containing a
phosphorothioate backbone (ISD-PS), which is an RNA analog.
These experiments raised the possibility that SAMHD1 is indir-
ectly interacting with RNA. Here we wanted to know whether
puriﬁed SAMHD1 directly interacts with RNA. For this purpose,
we tested the ability of full-length SAMHD1 puriﬁed from
baculovirus-infected insect cells to bind RNA (Fig. S1A and
Fig. 4A). As shown in Fig. 4A, puriﬁed SAMHD1 binds directly
ISD-PS in a dose dependent manner. To control for the bona ﬁde
nature of the puriﬁed SAMHD1 protein, we tested the tripho-
sphodeoxynucleotidase (dNTPase) activity of the protein. In
agreement with the previous ﬁndings, our puriﬁed full-length
recombinant SAMHD1 protein exhibits dGTP-dependent dTTPase
activity (Fig. 4B). The recombinant SAMHD1 protein hydrolyzes
0.004 ng of dTTP/mg of SAMHD1/min. These results indicated a
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as RNA.
Because SAMHD1 binds RNA, we tested the ability of RNA to
modulate the dNTPase activity of SAMHD1. For this purpose, we
measured the ability of puriﬁed recombinant SAMHD1 to hydro-
lyze a32P –TTP in the presence of the RNA analog ISD-PS (Fig. 4C).
Interestingly, the presence of double-stranded RNA in the reac-
tion inhibited the enzymatic activity of recombinant SAMHD1.Fig. 2. SAMHD1 oligomerization assay. Human 293 T cells were cotransfected
with similar amounts of a plasmid expressing SAMHD1-HA and SAMHD1-FLAG.
Lysed cells 24 h after transfection (Input) were incubated with anti-FLAG beads,
as described in Materials and Methods. FLAG-peptide elutions were analyzed by
Western blotting using anti-HA and anti-FLAG antibodies (Immunoprecipitation).
To control for background binding of SAMHD1-HA protein to anti-FLAG beads, we
performed similar experiments in 293T cells that were cotransfected with a
plasmid expressing SAMHD1-HA and the empty vector LPCX. Similar results were
obtained in three separate experiments and representative data is shown. WB,
Western blot; IP, Immunoprecipitation.
Fig. 3. Hetero-oligomerization of mutant and wild type SAMHD1 proteins. Human 293
plasmid either expressing wild type or mutant SAMHD1-FLAG proteins. Cells were lyse
FLAG antibodies (Input). Subsequently, lysates were immunoprecipitated by using ant
beads were eluted using FLAG peptide, and elutions were analyzed by Western blottin
were obtained in three independent experiments and representative data is shown. WThese results suggested that the enzymatic activity of SAMHD1 is
modulated by double-stranded RNA.
Next, we tested the ability of SAMHD1 variants expressed in
human 293 cells to bind RNA. To control for the bona ﬁde nature
of the immunoprecipitated SAMHD1 protein from human cells,
we tested its enzymatic activity (Fig. S1B). To assay the ability of
SAMHD1 variants to bind RNA, we tested the ability of SAMHD1
variants produced in human 293T cells to bind ISD-PS (Fig. 4D and
Table 1). Analysis of binding to RNA revealed that each and every
SAMHD1 variant containing a complete HD domain interacts with
RNA (Fig. 4D and Table 1). Moreover, we found that SAMHD1
variants containing the speciﬁc N-terminal (residues 112–328) or
C-terminal region (residues 329–582) of the HD domain interact
with RNA (Fig. 4D and Table 1). By contrast, the SAMHD1 variant
151–328 that exhibits a shorter N-terminal region of the HD
domain no longer binds RNA. These results indicated that the
N-terminal and C-terminal region of the HD domain are the
minimal protein segments with the ability to bind RNA. However,
it is also possible that the SAMHD1 variant 151–328 is a
misfolded protein.
Subcellular localization of SAMHD1 variants
Previous work has demonstrated that SAMHD1 is a nuclearly
localized protein (Brandariz-Nunez et al., 2012; Rice et al., 2009). Next
we investigated the subcellular localization of the SAMHD1 variants
studied in this work in the human HeLa cells (Fig. 5 and Table 1). In
agreement with our ﬁndings suggesting that the NLS of SAMHD1 is
located on the ﬁrst 15 amino acids (11KRPR14) of the protein
(Brandariz-Nunez et al., 2012), all SAMHD1 variants containing the
NLS localized to the nucleus of HeLa cells (Fig. 5 and Table 1). By
contrast, SAMHD1 variants missing the NLS were localized to either
the cytoplasm or the cytoplasm and the nucleus (Fig. 5 and Table 1).
In agreement with previous ﬁndings (Brandariz-Nunez et al., 2012),
these results demonstrated that SAMHD1 blocks HIV-1 infection
independent of its cellular localization.T cells were cotransfected with a plasmid expressing wild type SAMHD1-HA and a
d 24 h after transfection and analyzed by Western blotting using anti-HA and anti-
i-FLAG agarose beads, as described in Materials and methods. Anti-FLAG agarose
g using anti-HA and anti-FLAG antibodies (Immunoprecipitation). Similar results
B, Western blot; IP, Immunoprecipitation; WT, wild type.
Fig. 4. SAMHD1 binding to nucleic acids. (A) Increasing amounts of puriﬁed SAMHD1 protein from insect cell (Input) were incubated with the RNA analog ISD-PS
immobilized in StrepTactin Superﬂow afﬁnity resin as described in Materials and methods. Proteins bound to the resin were eluted and visualized by Western blotting
using anti-FLAG antibodies (Bound). Similar results were obtained in three independent experiments and a representative experiment is shown. (B) Enzymatic activity of
puriﬁed SAMHD1 (5.8 mM) was measured by measuring hydrolysis of dTTP in the presence of SAMHD1’s allosteric activator dGTP. The concentration of dTTP in the
sample was measured at the indicated time points. Experiments were performed in triplicates and standard deviation is shown. (C) dTTPase activity of recombinant
SAMHD1 was measured in the presence of the double-stranded RNA analog ISD-PS. Reaction products were separated by thin-layer chromatography using
polyethyleneimine cellulose. The results of three independent enzymatic reactions per treatment are shown. (D) Human 293T cells were transfected with plasmid
expressing the indicated wild type and mutant SAMHD1 protein. Lysed cells 24 h after transfection (Input) were incubated with ISD-PS immobilized in StrepTactin
Superﬂow afﬁnity resin. Similarly, eluted proteins from the resin were visualized by Western blotting using anti-FLAG antibodies (Bound). Similar results were obtained in
three independent experiments and a representative experiment is shown. ISD-PS, interferon-stimulatory DNA sequence containing a phosphorothioate backbone; WB,
Western blot; WT, wild type; CIP, calf intestine phosphatase.
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infection by different retroviruses
Because the HD domain of SAMHD1 potently blocks HIV-1
infection, we tested the ability of SAMHD1 and the HD domain to
block different retroviruses. For this purpose, we challenged PMA-
treated U937 cells expressing either SAMHD1 or the HD domain
(112–582) with increasing amounts of the indicated retrovirus
containing the green ﬂuorescent protein (GFP) as a reporter of
infection (Fig. 6A). As control, we performed similar infections in
PMA-treated U937 cells containing the empty vector LPCX. As
expected, wild type SAMHD1 blocked HIV-1 infection; however, the
sole HD domain was more effective in blocking HIV-1. Similarly, the
HD domain of SAMHD1 more potently blocked infection when
compared to wild type SAMHD1 when the following retroviru-
ses were tested (Fig. 6A): HIV-2, SIVmac, SIVmacDVpx, bovine
immunodeﬁciency virus (BIV), feline immunodeﬁciency virus (FIV),
N-tropic murine leukemia virus (N-MLV) and B-tropic murine leuke-
mia virus (B-MLV). Interestingly, equine infectious anemia virus
(EIAV) seems to partially overcome SAMHD1-mediated restriction
suggesting that EIAV has a mechanism to overcome SAMHD1. To
conﬁrm these observations using cells that endogenously expressSAMHD1, we challenged THP-1 cells either treated with PMA or
DMSOwith increasing amounts of the indicated retroviruses (Fig. 6B).
PMA-treated THP-1 cells potently block infection by HIV-1, HIV-2,
SIVmacDVpx, BIV, FIV, EIAV, N-MLV and B-MLV. By contrast, SIVmac
infection, which carries Vpx, was not blocked by PMA-treated THP-1
cells when compared to SIVmacDVpx. These results demonstrated the
wide range of retroviruses that can be inhibited by either expression
of SAMHD1 or the sole HD domain.Discussion
Here we studied the contribution of the different domains of
SAMHD1 to its antiviral activity. From these studies, we have learned
the following: (1) the SAM domain of SAMHD1 seems to be
dispensable for retroviral restriction, (2) the sole HD domain is
sufﬁcient for potent restriction of HIV-1 and other retroviruses, (3)
we have established a method to measure the ability of SAMHD1 to
oligomerize in mammalian cells, (4) an intact HD domain is required
for SAMHD1 oligomerization, (5) the N-terminal (residues 112–328)
and C-terminal (residues 329–582) regions of the HD domain are the
minimal protein sequences with the ability to bind RNA, (6) cytosolic
Fig. 5. Intracellular distribution of SAMHD1 mutant proteins in HeLa cells. HeLa
cells expressing the indicated SAMHD1-FLAG variants were ﬁxed and immunos-
tained using antibodi es against FLAG (red) as described in Materials and methods.
Cellular nuclei were stained by using DAPI (blue). Image quantiﬁcation for three
independent experiments is shown in Supplementary Table S1. Similar results
were obtained in three independent experiments and a representative experiment
is shown.
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retroviral infection more potently when compared to the full-length
SAMHD1, and (8) SAMHD1 and the HD domain of SAMHD1 potently
block infection of HIV-1, HIV-2, SIVmacDVpx, FIV, BIV, N-MLV and B-
MLV.
SAM domains can potentially interact with each other, with
other domains and with RNA (Qiao and Bowie, 2005; Rice et al.,
2009). However, the SAM domain of SAMHD1 seems to be
dispensable for the ability of SAMHD1 to block retroviral infection
or to bind RNA. Our oligomerization assays revealed that full-
length SAMHD1 does not interact with the SAMHD1 variant (1–
150) that contains the SAM domain, suggesting that the SAM
domain of SAMHD1 might not be interacting with itself in the
context of a dimeric SAMHD1; however, the SAMHD1 variant 1–
150 that contains the SAM domain might be a misfolded protein.
This work did not eliminate the possibility that the SAM domain
is involved in the regulation of SAMHD1’s enzymatic activity.
The fact that expression of the sole HD domain of SAMHD1 is
sufﬁcient to achieve potent retroviral restriction agrees with thenotion that dNTPs depletion is the only necessary step required
for restriction (Goldstone et al., 2011; Kim et al., 2012; Lahouassa
et al., 2012b; Powell et al., 2011). Interestingly, cycling U937 cells
expressing the HD domain of SAMHD1, which were not induced
to differentiate by PMA, were permissive to HIV-1 infection (data
not shown). These results suggested that in cycling cells the sole
HD domain undergoes a regulation that inhibits its enzymatic
activity. An alternative possibility is that the levels of dNTPs in
cycling U937 cells are high enough that having an enzymatically
active HD domain does not inﬂuence the overall levels of dNTPs.
This alternative possibility could be tested by studying the
sensitivity of HIV-1 infection in cycling U937 cells expressing
the HD domain to hydroxyurea, which is an inhibitor of ribonu-
cleotide reductase (RNR). The enzyme RNR is responsible for the
synthesis of deoxynucleotides, which provide the substrate for
synthesis of dNTPs. If the HD domain of SAMHD1 expressed in
cycling U937 cells is an enzymatically active HD domain, infection
of HIV-1 might be more sensitive to hydoxyurea when compared
to control U937 cells.
In agreement with the dimeric structure of SAMHD1 (Goldstone
et al., 2011), we demonstrated that SAMHD1 expressed in mamma-
lian cells is an oligomer by an assay that measures SAMHD1
oligomerization. However, our oligomerization assay has the limita-
tion that it does not provide information regarding the stoichiome-
try of the oligomer (i.e. dimer, trimer, etc). Besides this drawback,
this assay could be used as a surrogate to evaluate protein folding.
Using this assay, we demonstrated that an intact HD domain is
required for oligomerization. Interestingly, we observed that the
SAMHD1 variant HD206AA, which is a mutation on the active site of
SAMHD1, is defective for oligomerization (Fig. 3). This observation
raises the possibility that this mutant is enzymatically defective
because of a defect on oligomerization, suggesting that oligomeriza-
tion contributes to the enzymatic activity of SAMHD1. It will be
important to determine whether dimerization of the HD domain is
required for enzymatic activity and retroviral restriction.
Previous work demonstrated the ability of SAMHD1 to interact
with RNA (Goncalves et al., 2012). However, these experiments
used unpuriﬁed SAMHD1 protein in mammalian or bacterial
extracts raising the possibility that the observed interaction
between SAMHD1 and RNA is mediated by a second protein
present in the extract. Here we used puriﬁed SAMHD1 protein
from insect cells, and showed that enzymatically active SAMHD1
has the ability to directly interact with RNA. Furthermore, our
mapping studies revealed that the HD domain is the basic motif
required for the ability of SAMHD1 to bind RNA, as previously
suggested (Goncalves et al., 2012). Additionally, we found
SAMHD1 variants that are able to bind RNA but unable to
oligomerize, suggesting that oligomerization is not required for
RNA binding. Surprisingly, RNA binding to SAMHD1 dramatically
affected its enzymatic activity bringing up the possibility that
when SAMHD1 interacts with the RNA of a pathogen it allows the
recovery of cellular dNTPs, which might be beneﬁcial for the host
response.
In agreement with our previous observations (Brandariz-
Nunez et al., 2012), the subcellular localization of SAMHD1
variants did not inﬂuence SAMHD1’s ability to block retroviral
infection. These results suggested that dNTPs are depleted from
either the nucleus or cytoplasm.
Our ﬁndings showed that the sole HD domain restricts more
potently than the full-length SAMHD1. These results suggest that
the HD domain alone is more active as an enzyme, which
indirectly implies that the HD domain (SAMHD1 variant 112–
582) is missing regulatory parts of the protein that control
enzymatic activity. Future experiments will address the possibi-
lity that other regions of the SAMHD1 protein regulate the
enzymatic activity of the HD domain.
Fig. 6. Ability of SAMHD1 and the HD domain (112–582 variants) to block infection by different retroviruses. (A) PMA-treated human monocytic U937 cells stably
expressing either wild type SAMHD1 or the HD domain of SAMHD1 (SAMHD1 variant 112–582) were challenged with increasing amounts of the indicated retrovirus
expressing GFP as a reporter for infection. The percentage of GFP-positive cells was determined by ﬂow cytometry. (B) Human monocytic THP-1 cells were treated with
either PMA or DMSO (the solvent used to dissolve PMA). Treated cells were similarly challenged with increasing amounts of the indicated GFP-expressing retrovirus.
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Cell lines and plasmids
Human THP-1(ATCC#TIB-202) and U937 (ATCC#CRL-1593)
cells were grown in RPMI supplemented with 10% (v/v) fetal
bovine serum and 1% (v/v) penicilin/streptomycin. Human HeLa
cells (ATCC# CCL-2) were grown on DMEM supplemented with
10% fetal bovine serum and and 1% (w/v) penicilin/streptomycin.
LPCX-SAMHD1-HA and LPCX-SAMHD1-FLAG plasmids expressing
the codon optimized SAMHD1 fused to either HA or FLAG epitope
were previously described (Brandariz-Nunez et al., 2012). The
plasmids expressing SAMHD1 deletion mutants were created
using pLPCX-SAMHD1-FLAG as template and speciﬁc primers.
PCR products were digested and cloned into the EcoRI and ClaI
sites of pLPCX. Orientation of the inserts was conﬁrmed by
sequencing and restriction analysis.
Generation of U937 cells stably expressing SAMHD1 variants
Retroviral vectors encoding wild type or mutant SAMHD1
proteins fused to FLAG were created using the LPCX vector
(Clontech). Recombinant viruses were produced in 293T cells by
co-transfecting the LPCX plasmids with the pVPack-GP andpVPack-VSV-G packaging plasmids (Stratagene). The pVPack-
VSV-G plasmid encodes the vesicular stomatitis virus G envelope
glycoprotein, which allows efﬁcient entry into a wide range of
vertebrate cells (Yee et al., 1994). Transduced human monocytic
U937 cells were selected in 0.4 mg/ml puromycin (Sigma).
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) as previously described (Lienlaf et al., 2011).
Detection of proteins by Western blotting was performed using
anti-FLAG (Sigma), anti-SAMHD1 (Abnova), anti-GAPDH
(Ambion) or anti-HA (Sigma). Secondary antibodies against rabbit
and mouse conjugated to Alexa Fluor 680 were obtained from
Li-Cor. Bands were detected by scanning blots using the Li-Cor
Odyssey Imaging System in the 700 nm channel.
Infection with retroviruses expressing the green ﬂuorescent
protein (GFP)
Recombinant retroviruses expressing GFP, pseudotyped with the
VSV-G glycoprotein, were prepared as described (Diaz-Griffero et al.,
2008). For infections, 6104 cells seeded in 24-well plates were
either treated with 10 ng/ml phorbol-12-myristate-3-acetate (PMA)
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250 mg/ml. Subsequently, cells were incubated with the indicated
retrovirus for 48 h at 37 1C. The percentage of GFP-positive cells was
determined by ﬂow cytometry (Becton Dickinson). Viral stocks were
titrated by serial dilution on dog Cf2Th cells.
SAMHD1 oligomerization assay
Approximately 1.0107 human 293T cells were cotransfected
with plasmids encoding FLAG-tagged and HA-tagged mutant and
wild type SAMHD1 proteins. After 24 h, cells were lysed in 0.5 ml
of whole-cell extract (WCE) buffer (50 mM Tris [pH 8.0], 280 mM
NaCl, 0.5% IGEPAL, 10% glycerol, 5 mM MgCl2, 50 mg/ml ethidium
bromide, 50 U/ml benzonase tail [Roche]). Lysates were centri-
fuged at 14,000 rpm for 1 h at 4 1C. Post-spin lysates were then
pre-cleared using protein A-agarose (Sigma) for 1 h at 4 1C; a
small aliquot of each of these lysates was stored as input. Pre-
cleared lysates containing the tagged proteins were incubated
with anti-FLAG-agarose beads (Sigma) for 2 h at 4 1C. Anti-FLAG-
agarose beads were washed three times in WCE buffer, and
immune complexes were eluted using 200 mg of FLAG tripep-
tide/ml in WCE buffer. The eluted samples were separated by
SDS-PAGE and analyzed by Western blotting using either anti-HA
or anti-FLAG antibodies.
Nucleic-acid binding assay
Nucleic-acid binding assay was performed as previously
described (Goncalves et al., 2012). In brief, the synthetic DNA
phosphorothioate-containing interferon-stimulatory DNA (ISD-PS),
which is an RNA analog, was synthesized with a 50-biotin tag using
the following primers:
ISD sense 50-tacagatctactagtgatctatgactgatctgtacatgatctaca-30,
ISD antisense 50-tgtagatcatgtacagatcagtcatagatcactagtagatctgta-30
Sense and antisense primers were incubated at 65 1C for
20 min, and primers were allowed to anneal by cooling down to
room temperature. Annealed primers were immobilized on an
Ultralink Immobilized Streptavidin Plus Gel (Pierce). Cells were
lysed using TAP lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 5%
glycerol, 0.2% NP-40, 1.5 mM MgCl2, 25 mM NaF, 1 mM Na3VO4,
protease inhibitors) and lysates were cleared by centrifugation.
Cleared lysates (Input) were incubated with immobilized nucleic
acids at 4 1C on a rotary wheel for 2 h in the presence of 10 mg/ml
of Calf-thymus DNA (Sigma) as a competitor. Unbound proteins
were removed by three consecutive washes in TAP lysis buffer.
Bound proteins to nucleic acids (Bound) were eluted by boiling
samples in SDS sample buffer (63 mM Tris–HCl, 10% Glycerol 2%
SDS, 0.0025% Bromophenol Blue) and analyzed by Western blot-
ting using anti-FLAG antibodies (Sigma).
dNTP extraction and assay
2106 to 3106 cells were collected for each cell type. Cells
were washed twice with 1x PBS, pelleted and resuspended in ice
cold 65% methanol. Cells were vortexed for 2 min and incubated at
95 1C for 3 min. Cells were centrifuged at 14000 rpm for 3 min and
the supernatant was transferred to a new tube for the complete
drying of the methanol in a speed vac. The dried samples were
resuspended in molecular grade dH2O. An 18-nucleotide primer
labeled at the 50 end with 32 P (50-GTCCCTGTTCGGGCGCCA-30) was
annealed at a 1:2 ratio to four different 19-nucleotide templates (50-
NTGGCGCCCGAACAGGGAC-30), where ‘N’ represents the nucleotide
variation at the 50 end. Reaction condition contains 200 fmoles of
template primer, 2 ml of 0.5 mM dNTP mix for positive control or
dNTP cell extract, 4 ml of excess HIV-1 RT, 25 mM Tris–HCl, pH 8.0,
2 mM dithiothreitol, 100 mM KCl, 5 mM MgCl2, and 10 mMoligo(dT) to a ﬁnal volume of 20 mL. The reaction was incubated at
37 1C for 5 min before being quenched with 10 mL of 40 mM EDTA
and 99% (vol/vol) formamide at 95 1C for 5 min. The extended
primer products were resolved on a 14% urea–PAGE gel and
analyzed using a phosphoimager. The extended products were
quantiﬁed using QuantityOne software to quantify percent volume
of saturation. The quantiﬁed dNTP content of each sample was
accounted for based on its dilution factor, so that each sample
volumewas adjusted to obtain a signal within the linear range of the
assay (Kim et al., 2012; Lahouassa et al., 2012a).
Nucleotide hydrolysis reactions
5.8 mM SAMHD1 was incubated with 1 mM dTTP and 100 mM
dGTP in reaction buffer (50 mM Tris–HCl pH 8, 50 mM KCl, 5 mM
MgCl2, 0.1% Triton-X100) for 2 h at 37 1C. Reactions were termi-
nated by incubation at 75 1C for 10 min and diluted 20-fold into
12.5% acetonitrile containing 58 mM dCMP as a reference control.
HPLC: Dionex DNAPac PA100 column (450 mm2) was equili-
brated with running buffer (25 mM Tris–HCl pH 8, 0.5% acetoni-
trile) for 10 min, 99 ml sample was injected and eluted with a
linear gradient of 240 mM NH4Cl for 12 min, run at an isocratic
gradient with 240 mM NH4Cl for 5 min, and column was again
equilibrated with running buffer (Beckman Coulter System Gold
126 Solvent Module). Absorbance was measured with a Beckman
Coulter System Gold 166 Detector at 254 nm and dTTP abundance
was determined by integrating the area under each peak using 32
Karat 8.0 Software. dTTP levels were normalized by the amount of
dCMP detected in each diluted sample.
Assay to determine dNTPase activity of SAMHD1
Recombinant SAMHD1 (5 mM) was incubated with or without
100 mM dGTP, with or without 6 mM dsRNA analog, 500 mM dTTP
and 0.25 ml a32P-dTTP (PerkinElmer) in SAMHD1 reaction buffer
(50 mM Tris–HCl pH 8, 50 mM KCl, 5 mM MgCl2, 0.1% Triton-X
100) in a 17.5 ml ﬁnal volume. Reactions were initiated by
addition of SAMHD1, incubated for 1 h at 37 1C, and terminated
by incubation for 10 min at 70 1C. The no enzyme control reaction
and the antarctic phosphatase reaction contained both dGTP and
dsRNA. The antarctic phosphatase reaction (2 ml, New England
BioLabs) was used to show the mobility of monophosphates on
the plate as a comparison to triphosphate mobility. Reactions
were spotted (0.5 ml) on a TLC PEI Cellulose F plate (EMD
Chemicals) and separated in a 0.8 M LiCl solvent. Product forma-
tion was analyzed on a Bio-Rad Personal Molecular Imager.
Transfections and immunoﬂuorescence microscopy
Transfections of cell monolayers were performed using
Lipofectamine Plus reagent (Invitrogen), according to the manufac-
turer’s instructions. Transfections were incubated at 37 1C for 24 h.
Indirect immunoﬂuorescence microscopy was perfomed as pre-
viously described (Diaz-Griffero et al., 2002). Transfected monolayers
grown on coverslips were washed twice with PBS1X (137mM NaCl,
KCl 2.7 mM, Na2HPO4 2H2O 10mM, KH2PO4 mM) and ﬁxed for
15 min in 3.9% paraformaldehyde in PBS1X. Fixed cells were washed
twice in PBS1X, permeabilized for 4 min in permeabilizing buffer
(0.5% Triton X-100 in PBS), and then blocked in PBS1X containing 2%
bovine serum albumin (blocking buffer) for 1 h at room temperature.
Cells were then incubated for 1 h at room temperature with primary
antibodies diluted in blocking buffer. After three washes with PBS,
cells were incubated for 30min in secondary antibodies and 1 mg of
DAPI (49, 69-diamidino-2-phenylindole)/ml. Samples were mounted
for ﬂuorescence microscopy by using the ProLong Antifade Kit
(Molecular Probes, Eugene, OR). Images were obtained with a Zeiss
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was performed using the software AxioVision V4.8.1.0 (Carl Zeiss
Imaging Solutions).
Construction of recombinant baculovirus expressing OSF-SAMHD1
Recombinant baculovirus was generated using the Bac-to-Bac
system (Invitrogen) following the manufacturer’s instructions. For
construction of the transfer vector, full-length SAMHD1 was
ampliﬁed by PCR using speciﬁc primers and cloned into the EcoRI
and XbaI sites of the pFastBac-1 vector containing an OSF epitope
(One-Strep and Flag) previously cloned into BamHI and EcoRI
sites of the plasmid. The correctness of the construct was
conﬁrmed by sequencing. The pFastBac1-OSF-SAMHD1 vector
was recombined into the bacmid by transformation of DH10 Bac
cells (Invitogen). The recombinant bacmid was obtained accord-
ing to the supplier’s protocol. Single colonies were grown to
stationary phase in 2 ml of LB medium supplemented with the
necessary antibiotics (50 mg/ml kanamycin, 7 mg/ml gentamicin,
and 10 mg/ml tetracycline shaking at 300 rpm) for up 24 h at
37 1C. Bacterial pellets were resuspended in 0.3 ml of Solution I
[15 mM Tris–HCl (pH 8.0), 10 mM EDTA, 100 mg/ml RNase A] and
0.3 ml of Solution II (0.2 N NaOH, 1% SDS) and incubated at room
temperature for 5 min. Samples were treated with 0.3 ml of 3 M
potassium acetate (pH 5.5) on ice for 10 min and cebtrifugated for
10 min at 14,000g. The supernatant was transferred to a tube
containing isopropanol and incubated on ice for 10 min. The DNA
was pelleted by centrifugation for 15 min at 14,000g at room
temperature. The pellets were washed with 0.5 ml of 70% ethanol.
The pellet was air dried at room temperature. DNA samples were
resuspended in 40 ml milli-Q water. The presence of the SAMHD1
gene in the bacmids was conﬁrmed by PCR using the pUC/M13
forward and reverse primers described by Invitrogen. The PCR
products were sequenced to conﬁrm the presence of the insert
containing the OSF-SAMHD1 construct. The bacmid was then
used to generate the corresponding recombinant baculovirus
according to the supplier’s protocol as described (Brandariz-
Nunez et al., 2010a, b). Brieﬂy, the bacmid was transfected into
Spodoptera frugiperda (SF9) cells using Lipofectamine Plus
reagent (Invitrogen). Cells were incubated at 28 1C in SF-900 II
serum-free insect cell medium (Invitrogen) for 3 days, and
recombinant viruses expressing full-length SAMHD1 were
havested (P1 viral stock). For ampliﬁcation of P1 viral stock, a
monolayer culture (2106 cells/ml) was infected with 0.5 ml of a
P1 viral stock. The P2 viral stock was harvested 3 days post-
infection. Expression of OSF-SAMHD1 was analyzed in SF9 cells
infected with P2 viral sotcks by coomassie stain and Western
blotting using anti-FLAG and anti-SAMHD1 antibodies.
SAMHD1 expression in insect cells
7.5108 Sf9 insect cells growing in suspension were infected
with 5 PFU/cell of the recombinant baculovirus and incubated at
28 1C for 72 h. All subsequent steps were carried out at 4 1C. Cells
were collected by centrifugation at 500g for 8 min, resuspended
in 60 ml of lysis buffer (250 mM NaCl, 50 mM Tris [pH 8.0], 1.5%
Triton X-100, 1 mM TCEP, and mammalian protease inhibitor
cocktail [Sigma]). The lysate was clariﬁed by centrifugation
(20,000g, 40 min), ﬁltered (0.45 mm), and incubated in 1.5 ml
StrepTactin Superﬂow afﬁnity resin (Qiagen). The bound protein
was washed three three-times with 15 ml of buffer (50 mM NaCl,
50 mM Tris [pH 8.0], 1 mM TCEP) and eluted with washing buffer
supplemented with 2.5 mM D-desthiobiotin. The eluate was
analyzed by SDS-PAGE and Western blotting using anti-FLAG or
anti-SAMHD1 antibodies.Acknowledgments
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